AARTI PHARMALABS LIMITED GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPORT
Grifols Shares Down 4.8% After Gotham City Research Issues Repor…
May 14, 2024 at 03:12 am EDT
Share
Share
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 571.4 INR | -1.83% |
|
-7.12% | +13.26% |
| May. 14 | GRIFOLS SHARES DOWN 4.8% AFTER GOTHAM CITY RESEARCH ISSUES REPOR… | RE |
| May. 13 | Aarti Pharmalabs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.26% | 635M | |
| +38.32% | 727B | |
| -7.84% | 354B | |
| +15.61% | 328B | |
| +0.16% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.17% | 164B | |
| -1.72% | 164B |
- Stock Market
- Equities
- AARTIPHARM Stock
- News Aarti Pharmalabs Limited
- Grifols Shares Down 4.8% After Gotham City Research Issues Repor…
